Rimegepant shows promise in acute migraine attacks

Rimegepant shows promise in acute migraine attacks

Richard B. Lipton et al found that the drug rimegepant could eliminate pain and bothersome symptoms on treating patients with migraine in a large-scale phase 3 trial. Rimegepant is an oral calcitonin gene-related peptide receptor antagonist. Researchers randomly assigned adults with at least a 1-year history of migraine and two to eight migraine attacks of moderate or severe intensity per month to receive rimegepant orally at a dose of 75 mg or matching placebo for the treatment of a single migraine attack. Of a total 1186 patients involved in the study, 594 patients received rimegepant while 592 patients were subjected to placebo treatment. About 88.7% of the candidates were women. The percentage of patients who were
pain-free 2 hours after receiving the dose was 19.6% in the rimegepant group and 12.0% in the placebo group. The percentage of patients who were free from their most bothersome symptom 2 hours after the dose was 37.6% in the rimegepant group and 25.2% in the placebo group. The results confirm rimegepant mechanism of action—blocking the CGRP pathway—effectively relieves pain and associated symptoms that occur during acute migraine
attacks.

Straight Talk

View More